PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
3.30%
Revenue growth below 50% of VET's 9.46%. Michael Burry would check for competitive disadvantage risks.
22.46%
Cost growth above 1.5x VET's 4.41%. Michael Burry would check for structural cost disadvantages.
-17.94%
Gross profit decline while VET shows 12.23% growth. Joel Greenblatt would examine competitive position.
-20.56%
Margin decline while VET shows 2.53% expansion. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.32%
Other expenses growth while VET reduces costs. John Neff would investigate differences.
11.03%
Operating expenses growth above 1.5x VET's 4.14%. Michael Burry would check for inefficiency.
19.27%
Total costs growth above 1.5x VET's 4.28%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
9.05%
Similar D&A growth to VET's 11.64%. Walter Schloss would investigate industry patterns.
-20.43%
EBITDA decline while VET shows 16.37% growth. Joel Greenblatt would examine position.
-31.87%
EBITDA margin decline while VET shows 6.31% growth. Joel Greenblatt would examine position.
-40.26%
Operating income decline while VET shows 20.61% growth. Joel Greenblatt would examine position.
-42.17%
Operating margin decline while VET shows 10.18% growth. Joel Greenblatt would examine position.
154.55%
Other expenses growth while VET reduces costs. John Neff would investigate differences.
-27.82%
Pre-tax income decline while VET shows 6.91% growth. Joel Greenblatt would examine position.
-30.13%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-106.94%
Tax expense reduction while VET shows 74326.67% growth. Joel Greenblatt would examine advantage.
15.45%
Net income growth while VET declines. John Neff would investigate advantages.
11.76%
Net margin growth while VET declines. John Neff would investigate advantages.
16.59%
EPS growth while VET declines. John Neff would investigate advantages.
16.59%
Diluted EPS growth while VET declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-0.73%
Diluted share reduction while VET shows 1.71% change. Joel Greenblatt would examine strategy.